113 related articles for article (PubMed ID: 26143926)
1. The high-resolution crystal structure of phosphatidylinositol 4-kinase IIβ and the crystal structure of phosphatidylinositol 4-kinase IIα containing a nucleoside analogue provide a structural basis for isoform-specific inhibitor design.
Klima M; Baumlova A; Chalupska D; Hřebabecký H; Dejmek M; Nencka R; Boura E
Acta Crystallogr D Biol Crystallogr; 2015 Jul; 71(Pt 7):1555-63. PubMed ID: 26143926
[TBL] [Abstract][Full Text] [Related]
2. The structural basis for calcium inhibition of lipid kinase PI4K IIalpha and comparison with the apo state.
Baumlova A; Gregor J; Boura E
Physiol Res; 2016 Dec; 65(6):987-993. PubMed ID: 27539108
[TBL] [Abstract][Full Text] [Related]
3. The crystal structure of the phosphatidylinositol 4-kinase IIα.
Baumlova A; Chalupska D; Róźycki B; Jovic M; Wisniewski E; Klima M; Dubankova A; Kloer DP; Nencka R; Balla T; Boura E
EMBO Rep; 2014 Oct; 15(10):1085-92. PubMed ID: 25168678
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 4-kinase type IIalpha is targeted specifically to cellugyrin-positive glucose transporter 4 vesicles.
Xu Z; Huang G; Kandror KV
Mol Endocrinol; 2006 Nov; 20(11):2890-7. PubMed ID: 16772528
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and modular synthesis of novel PI4K class II inhibitors bearing a 4-aminoquinazoline scaffold.
Misehe M; Klima M; Matoušová M; Chalupská D; Dejmek M; Šála M; Mertlíková-Kaiserová H; Boura E; Nencka R
Bioorg Med Chem Lett; 2022 Nov; 76():129010. PubMed ID: 36184029
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Charnley AK; Convery MA; Lakdawala Shah A; Jones E; Hardwicke P; Bridges A; Ouellette M; Totoritis R; Schwartz B; King BW; Wisnoski DD; Kang J; Eidam PM; Votta BJ; Gough PJ; Marquis RW; Bertin J; Casillas L
Bioorg Med Chem; 2015 Nov; 23(21):7000-6. PubMed ID: 26455654
[TBL] [Abstract][Full Text] [Related]
7. Research progress on phosphatidylinositol 4-kinase inhibitors.
Li G; Wu Y; Zhang Y; Wang H; Li M; He D; Guan W; Yao H
Biochem Pharmacol; 2024 Feb; 220():115993. PubMed ID: 38151075
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 4-kinases: Function, structure, and inhibition.
Boura E; Nencka R
Exp Cell Res; 2015 Oct; 337(2):136-45. PubMed ID: 26183104
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of apo and inhibitor-bound TGFβR2 kinase domain: insights into TGFβR isoform selectivity.
Tebben AJ; Ruzanov M; Gao M; Xie D; Kiefer SE; Yan C; Newitt JA; Zhang L; Kim K; Lu H; Kopcho LM; Sheriff S
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):658-74. PubMed ID: 27139629
[TBL] [Abstract][Full Text] [Related]
10. Localization of a highly active pool of type II phosphatidylinositol 4-kinase in a p97/valosin-containing-protein-rich fraction of the endoplasmic reticulum.
Waugh MG; Minogue S; Anderson JS; Balinger A; Blumenkrantz D; Calnan DP; Cramer R; Hsuan JJ
Biochem J; 2003 Jul; 373(Pt 1):57-63. PubMed ID: 12650639
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin gallate (EGCG) inhibits type II phosphatidylinositol 4-kinases: a key component in pathways of phosphoinositide turnover.
Sinha RK; Patel RY; Bojjireddy N; Datta A; Subrahmanyam G
Arch Biochem Biophys; 2011 Dec; 516(1):45-51. PubMed ID: 21964243
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of cAMP-dependent protein kinase complexed with the peptide inhibitor PKI(5-24) and adenosine.
Narayana N; Cox S; Shaltiel S; Taylor SS; Xuong N
Biochemistry; 1997 Apr; 36(15):4438-48. PubMed ID: 9109651
[TBL] [Abstract][Full Text] [Related]
13. A large scale high-throughput screen identifies chemical inhibitors of phosphatidylinositol 4-kinase type II alpha.
Sengupta N; Jović M; Barnaeva E; Kim DW; Hu X; Southall N; Dejmek M; Mejdrova I; Nencka R; Baumlova A; Chalupska D; Boura E; Ferrer M; Marugan J; Balla T
J Lipid Res; 2019 Mar; 60(3):683-693. PubMed ID: 30626625
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
15. Conformational changes during the catalytic cycle of gluconate kinase as revealed by X-ray crystallography.
Kraft L; Sprenger GA; Lindqvist Y
J Mol Biol; 2002 May; 318(4):1057-69. PubMed ID: 12054802
[TBL] [Abstract][Full Text] [Related]
16. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.
Berndt A; Miller S; Williams O; Le DD; Houseman BT; Pacold JI; Gorrec F; Hon WC; Liu Y; Rommel C; Gaillard P; Rückle T; Schwarz MK; Shokat KM; Shaw JP; Williams RL
Nat Chem Biol; 2010 Feb; 6(2):117-24. PubMed ID: 20081827
[TBL] [Abstract][Full Text] [Related]
17. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
[TBL] [Abstract][Full Text] [Related]
18. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
19. Type III phosphatidylinositol 4 kinases: structure, function, regulation, signalling and involvement in disease.
Dornan GL; McPhail JA; Burke JE
Biochem Soc Trans; 2016 Feb; 44(1):260-6. PubMed ID: 26862213
[TBL] [Abstract][Full Text] [Related]
20. Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases.
Li YP; Mikrani R; Hu YF; Faran Ashraf Baig MM; Abbas M; Akhtar F; Xu M
Eur J Pharmacol; 2021 Sep; 907():174300. PubMed ID: 34217706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
